Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer
Open Access
- 12 June 2021
- journal article
- research article
- Published by Springer Nature in Nano-Micro Letters
- Vol. 13 (1) , 1-15
Abstract
The highly immunosuppressive microenvironment after surgery has a crucial impact on the recurrence and metastasis in breast cancer patients. Programmable delivery of immunotherapy-involving combinations through a single drug delivery system is highly promising, yet greatly challenging, to reverse postoperative immunosuppression. Here, an injectable hierarchical gel matrix, composed of dual lipid gel (DLG) layers with different soybean phosphatidylcholine/glycerol dioleate mass ratios, was developed to achieve the time-programmed sequential delivery of combined cancer immunotherapy. The outer layer of the DLG matrix was thermally responsive and loaded with sorafenib-adsorbed graphene oxide (GO) nanoparticles. GO under manually controlled near-infrared irradiation generated mild heat and provoked the release of sorafenib first to reeducate tumor-associated macrophages (TAMs) and promote an immunogenic tumor microenvironment. The inner layer, loaded with anti-CD47 antibody (aCD47), could maintain the gel state for a much longer time, enabling the sustained release of aCD47 afterward to block the CD47-signal regulatory protein α (SIRPα) pathway for a long-term antitumor effect. In vivo studies on 4T1 tumor-bearing mouse model demonstrated that the DLG-based strategy efficiently prevented tumor recurrence and metastasis by locally reversing the immunosuppression and synergistically blocking the CD47-dependent immune escape, thereby boosting the systemic immune responses.Keywords
This publication has 52 references indexed in Scilit:
- XB130 promotes proliferation and invasion of gastric cancer cellsJournal of Translational Medicine, 2014
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophagesInternational Immunopharmacology, 2010
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Exploring the full spectrum of macrophage activationNature Reviews Immunology, 2008
- The anticancer immune response: indispensable for therapeutic success?Journal of Clinical Investigation, 2008
- Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and MetastasisCell, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003
- Alternative activation of macrophagesNature Reviews Immunology, 2003